ReviewDrug Saf2011
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
- Journal
- Drug Saf
- Published
- 1 March 2011
- Citations
- 6
- Type
- Review
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try